Short Interest in Celularity Inc. (NASDAQ:CELU) Grows By 67.4%

Celularity Inc. (NASDAQ:CELU) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 287,400 shares, a growth of 67.4% from the January 31st total of 171,700 shares. Approximately 2.6% of the company’s stock are sold short. Based on an average daily volume of 167,600 shares, the short-interest ratio is currently 1.7 days.

Celularity Stock Up 0.9 %

CELU stock traded up $0.01 during midday trading on Monday, reaching $1.17. 294,252 shares of the company were exchanged, compared to its average volume of 157,296. The stock’s 50-day simple moving average is $2.07 and its 200 day simple moving average is $2.40. Celularity has a 1-year low of $1.08 and a 1-year high of $7.97.

Celularity (NASDAQ:CELU) last announced its quarterly earnings results on Friday, December 6th. The company reported ($0.73) EPS for the quarter. Celularity had a negative return on equity of 119.53% and a negative net margin of 72.72%.

Institutional Trading of Celularity

Several institutional investors and hedge funds have recently made changes to their positions in the company. Keynote Financial Services LLC increased its position in Celularity by 90.1% during the fourth quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock worth $52,000 after buying an additional 11,863 shares during the period. Two Sigma Investments LP acquired a new position in shares of Celularity in the 4th quarter valued at $93,000. Biltmore Family Office LLC purchased a new stake in Celularity in the 4th quarter valued at $73,000. Finally, C V Starr & Co. Inc. acquired a new stake in Celularity during the 4th quarter worth $1,589,000. 19.02% of the stock is owned by hedge funds and other institutional investors.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.